Gennex Laboratories Ltd
Incorporated in 1995, Gennex Laboratories Ltd manufactures Bulk Drugs and Intermediaries[1]
- Market Cap ₹ 368 Cr.
- Current Price ₹ 16.2
- High / Low ₹ 21.9 / 5.75
- Stock P/E 38.6
- Book Value ₹ 4.77
- Dividend Yield 0.00 %
- ROCE 10.7 %
- ROE 7.35 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 40.4% CAGR over last 5 years
Cons
- Stock is trading at 3.39 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.19%
- The company has delivered a poor sales growth of 8.26% over past five years.
- Promoter holding is low: 18.4%
- Company has a low return on equity of 9.03% over last 3 years.
- Earnings include an other income of Rs.3.92 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
24.56 | 29.93 | 34.99 | 31.90 | 38.52 | 41.89 | 43.78 | 55.75 | 55.55 | 59.65 | 61.21 | 65.10 | 63.61 | |
22.94 | 28.40 | 33.36 | 29.88 | 34.32 | 37.36 | 41.58 | 51.73 | 52.31 | 53.12 | 55.83 | 60.51 | 53.01 | |
Operating Profit | 1.62 | 1.53 | 1.63 | 2.02 | 4.20 | 4.53 | 2.20 | 4.02 | 3.24 | 6.53 | 5.38 | 4.59 | 10.60 |
OPM % | 6.60% | 5.11% | 4.66% | 6.33% | 10.90% | 10.81% | 5.03% | 7.21% | 5.83% | 10.95% | 8.79% | 7.05% | 16.66% |
0.08 | 0.02 | 0.21 | 0.19 | 0.17 | 0.12 | 0.91 | 0.78 | 1.06 | 0.15 | 1.38 | 3.40 | 3.92 | |
Interest | 0.30 | 0.28 | 0.32 | 0.48 | 0.50 | 0.71 | 0.73 | 0.79 | 0.75 | 0.74 | 0.88 | 1.23 | 1.41 |
Depreciation | 0.74 | 0.80 | 0.82 | 0.89 | 0.84 | 0.84 | 0.92 | 0.98 | 1.00 | 0.88 | 0.79 | 0.74 | 0.80 |
Profit before tax | 0.66 | 0.47 | 0.70 | 0.84 | 3.03 | 3.10 | 1.46 | 3.03 | 2.55 | 5.06 | 5.09 | 6.02 | 12.31 |
Tax % | 42.42% | 17.02% | 70.00% | 22.62% | 22.77% | 12.90% | 42.47% | 26.40% | 27.06% | 20.16% | 22.99% | 24.09% | |
0.38 | 0.40 | 0.21 | 0.65 | 2.34 | 2.70 | 0.84 | 2.22 | 1.86 | 4.04 | 3.92 | 4.56 | 9.54 | |
EPS in Rs | 0.02 | 0.02 | 0.01 | 0.03 | 0.12 | 0.14 | 0.04 | 0.12 | 0.10 | 0.21 | 0.21 | 0.26 | 0.54 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 8% |
3 Years: | 5% |
TTM: | -6% |
Compounded Profit Growth | |
---|---|
10 Years: | 27% |
5 Years: | 40% |
3 Years: | 36% |
TTM: | 142% |
Stock Price CAGR | |
---|---|
10 Years: | 35% |
5 Years: | 46% |
3 Years: | 51% |
1 Year: | 175% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 8% |
3 Years: | 9% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12.65 | 12.65 | 12.65 | 12.65 | 12.65 | 12.65 | 12.65 | 12.65 | 12.65 | 12.65 | 12.65 | 18.02 | 17.98 |
Reserves | 12.13 | 12.53 | 12.74 | 12.88 | 15.59 | 18.29 | 19.13 | 21.35 | 23.20 | 27.24 | 31.35 | 61.00 | 66.63 |
1.90 | 2.41 | 3.19 | 3.84 | 2.43 | 3.84 | 2.47 | 4.54 | 4.98 | 7.36 | 10.12 | 0.98 | 3.54 | |
7.70 | 8.76 | 11.01 | 9.84 | 11.12 | 14.43 | 16.22 | 13.37 | 16.29 | 11.83 | 14.09 | 16.22 | 16.21 | |
Total Liabilities | 34.38 | 36.35 | 39.59 | 39.21 | 41.79 | 49.21 | 50.47 | 51.91 | 57.12 | 59.08 | 68.21 | 96.22 | 104.36 |
16.19 | 15.97 | 16.11 | 14.70 | 15.46 | 15.51 | 15.58 | 15.64 | 14.93 | 14.13 | 13.70 | 15.18 | 14.84 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 | 7.01 | 8.26 | 8.26 |
11.18 | 13.37 | 16.47 | 17.50 | 19.20 | 26.46 | 27.88 | 29.26 | 35.18 | 37.94 | 47.50 | 72.78 | 81.26 | |
Total Assets | 34.38 | 36.35 | 39.59 | 39.21 | 41.79 | 49.21 | 50.47 | 51.91 | 57.12 | 59.08 | 68.21 | 96.22 | 104.36 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2.12 | -1.73 | 0.48 | 0.21 | 3.35 | -0.11 | 3.16 | 1.88 | -1.67 | -1.44 | 6.64 | -14.45 | |
-0.85 | -0.57 | -0.90 | -0.20 | -1.15 | -0.97 | -0.67 | -0.99 | -0.22 | -0.02 | -1.26 | -0.77 | |
0.05 | 0.23 | 0.45 | 0.18 | -1.92 | 0.86 | -2.10 | 1.25 | -0.35 | 1.62 | 1.87 | 21.35 | |
Net Cash Flow | 1.32 | -2.07 | 0.03 | 0.19 | 0.29 | -0.22 | 0.39 | 2.13 | -2.23 | 0.16 | 7.24 | 6.14 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 45.18 | 48.90 | 50.59 | 70.83 | 65.95 | 89.75 | 87.21 | 68.09 | 41.26 | 54.77 | 67.44 | 49.45 |
Inventory Days | 49.55 | 33.72 | 28.81 | 22.75 | 47.42 | 42.59 | 30.91 | 57.35 | 78.28 | 49.91 | 71.85 | 132.82 |
Days Payable | 99.55 | 103.09 | 117.38 | 120.89 | 113.55 | 139.40 | 160.77 | 87.81 | 85.65 | 59.06 | 71.85 | 57.58 |
Cash Conversion Cycle | -4.82 | -20.46 | -37.98 | -27.32 | -0.18 | -7.07 | -42.65 | 37.64 | 33.90 | 45.62 | 67.44 | 124.69 |
Working Capital Days | 24.67 | 55.49 | 64.68 | 87.99 | 75.52 | 106.48 | 92.54 | 86.03 | 119.45 | 152.61 | 147.77 | 239.86 |
ROCE % | 3.65% | 2.84% | 3.63% | 4.56% | 11.89% | 11.64% | 6.32% | 10.50% | 8.04% | 14.01% | 11.78% | 10.74% |
Documents
Announcements
- Closure of Trading Window 29 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the quarter and Nine Months Ended December 31, 2023 announced by the Board in its …
- Dr.S.CH. DHARMA RAO Appointed As An Additional Director In The Capacity Of Non-Executive Director Of The Company 14 Feb
- Results - Financial Results For Quarter And Nine Months Ended December 31, 2023 14 Feb
- Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On 14.02.2024 - Scrip Code: 531739/GENNEX 14 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2008
from bse
Business Overview:[1][2]
GLL is an ISO 9001:2008, TUV, ISO 14001 and OSHAS 18000 certified vertically integrated Active Pharmaceutical Ingredient manufacturer & exporter of Bulk Drugs, Intermediates and Biotech Products in the form of Expectorants,
Muscle Relaxants, Analgesic and Anti Fungal, etc.